Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;27(6):347–350. doi: 10.1002/clc.4960270610

Beta1‐adrenergic receptor gene polymorphisms and response to Beta1‐adrenergic receptor blockade in patients with essential hypertension

J Karlsson 1, L Lind 1,2, P Hallberg 1, K Michaëlsson 3, L Kurland 1, T Kahan 4, K Malmqvist 4, K P Öhman 2,5, F Nyström 5,6, H Melhus 1,✉
PMCID: PMC6654438  PMID: 15237695

Abstract

Background: Studies suggest that the Ser49Gly and Arg389Gly polymorphisms in the β1‐adrenergic receptor might be of functional importance for the cardiovascular system. Both have been associated with altered receptor activity in vitro, and with hypertension and cardiac failure in vivo.

Hypothesis: The aim of this study was to test whether these polymorphisms were associated with the change in heart rate or blood pressure in patients with essential hypertension and left ventricular (LV) hypertrophy treated with the β1‐adrenergic receptor blocker atenolol.

Methods: Blood pressure and heart rate were measured in 101 hypertensive patients with echocardiographically verified LV hypertrophy, randomized in a double‐blind study to treatment with either the β1 ‐adrenergic receptor blocker atenolol or the angiotensin II type I receptor antagonist irbesartan. Changes in blood pressure and heart rate were evaluated after 12 weeks. Beta1‐adrenergic receptor genotyping was performed using polymerase chain reaction and restriction fragment length polymorphism.

Results: We found no significant associations between the changes in the measured variables and either of the two polymorphisms. However, carriers of the 49Gly allele showed a tendency toward a greater reduction in heart rate compared with patients with the Ser/Ser49 genotype (p = 0.06).

Conclusions: The Ser49Gly and Arg389Gly β1‐adrenergic receptor polymorphisms do not seem to exert a major effect on the changes in heart rate and blood pressure during 12 weeks of treatment with atenolol in patients with essential hypertension and LV hypertrophy.

Keywords: beta1‐adrenergic receptor, polymorphism, gene, pharmacogenetics, hypertension, atenolol, adrenoceptor

Full Text

The Full Text of this article is available as a PDF (32.3 KB).

References

  • 1. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in beta1‐adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96: 7059–7064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP Jr, Barsh GS, Bernstein D, Kobilka BK: Targeted disruption of the mouse beta1‐adrenergic receptor gene: Developmental and cardiovascular effects. Proc Natl Acad Sci USA 1996; 93: 7375–7380 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK: Cardiovascular and metabolic alterations in mice lacking both beta1‐and beta2‐adrenergic receptors. J Biol Chem 1999; 274: 16701–16708 [DOI] [PubMed] [Google Scholar]
  • 4. Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA: Structure and function of G protein‐coupled receptors. Ann Rev Biochem 1994; 63: 101–132 [DOI] [PubMed] [Google Scholar]
  • 5. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, Tiret L, Poirier O, Desnos M, Jullières Y, Amouyel P, Roizes G, Dorent R, Schwartz K, Komajda M: Characterization of a unique genetic variant in the beta1‐adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol 1999; 31: 1025–1032 [DOI] [PubMed] [Google Scholar]
  • 6. Maqbool A, Hall AS, Ball SG, Balmforth AJ: Common polymorphisms of beta1‐adrenoceptor: Identification and rapid screening assay (letter). Lancet 1999; 353: 897 [DOI] [PubMed] [Google Scholar]
  • 7. Mason DA, Moore JD, Green SA, Liggett SB: A gain‐of‐function polymorphism in a G‐protein coupling domain of the human beta1‐adrenergic receptor. J Biol Chem 1999; 274: 12670–12674 [DOI] [PubMed] [Google Scholar]
  • 8. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB: Racial differences in the frequencies of cardiac beta(1)‐adrenergic receptor polymorphisms: Analysis of c145A > G and c1165G > C (letter). Hum Mutat 1999; 14: 271 [DOI] [PubMed] [Google Scholar]
  • 9. Börjesson M, Magnusson Y, Hjalmarson A, Andersson B: A novel polymorphism in the gene coding for the beta(1)‐adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21: 1853–1858 [DOI] [PubMed] [Google Scholar]
  • 10. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Öhman KP, Nyström F, Hagg A, Lind L: Angiotensin‐converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783–1787 [DOI] [PubMed] [Google Scholar]
  • 11. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Öhman P, Nyström F, Hagg A, Lind L: Aldosterone synthase (CYP11B2) −344 C/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15: 389–393 [DOI] [PubMed] [Google Scholar]
  • 12. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller‐Brunotte R, Nyström F, Öhman KP, Osbakken MD, Ostergern J: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–1176 [DOI] [PubMed] [Google Scholar]
  • 13. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y: The myocardium‐protective Gly49 variant of the beta 1‐adrenergic receptor exhibits constitutive activity and increased desensitization and downregulation. J Biol Chem 2002; 277: 30429–30435 [DOI] [PubMed] [Google Scholar]
  • 14. Rathz DA, Brown KM, Kramer LA, Liggett SB: Amino acid 49 polymorphisms of the human beta1‐adrenergic receptor affect agonist‐promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155–160 [DOI] [PubMed] [Google Scholar]
  • 15. Ranade K, Jorgenson E, Sheu WH, Pei D, Hsiung CA, Chiang FT, Chen YD, Pratt R, Olshen RA, Curb D, Cox DR, Botstein D, Risch N: A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70: 935–942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Bengtsson K, Melander O, Orho‐Melander M, Lindblad U, Ranstam J, Rastam L, Groop L: Polymorphism in the beta(1)‐adrenergic receptor gene and hypertension. Circulation 2001; 104: 187–190 [DOI] [PubMed] [Google Scholar]
  • 17. Xie HG, Dishy V, Sofowora G, Kim RB, Landau R, Smiley RM, Zhou HH, Wood AJ, Harris P, Stein CM: Arg389Gly beta 1‐adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11: 191–197 [DOI] [PubMed] [Google Scholar]
  • 18. Buscher R, Belger H, Eilmes KJ, Tellkamp R, Radke J, Dhein S, Hoyer PF, Michel MC, Insel PA, Brodde OE: In‐vivo studies do not support a major functional role for the Gly389Arg beta 1‐adrenoceptor polymorphism in humans. Pharmacogenetics 2001; 11: 199–205 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES